← Leaderboards
Kurt Francis Hauser
University Of Kentucky
$27,368,955
Attributed
$38,018,410
Total exposure
18
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,018,410 · 18
By mechanism
R01$30,455,344 · 13
P01$5,025,969 · 1
K02$1,297,135 · 1
R21$1,239,962 · 3
Top collaborators
- Pamela E Knapp21 shared
- Yan Zhang7 shared
- Aron H Lichtman6 shared
- Dana E Selley6 shared
- Laura J Sim-Selley6 shared
- Viktor Yarotskyy4 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Pamela E Knapp$12,958,922
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsAstrocytesHiv Envelope Protein Gp120OpioidHiv-1Pharmaceutical PreparationsOpioid AbuseOpioid ReceptorInjuryMicrogliaIn VivoNeurogliaMorphineCorpus Striatum StructureCellsMediatingSignal TransductionAffectEventPathologyHomeostasisIn VitroCessation Of LifeNeuronal Injury
Grant awards (91)
pTau-related neuron and cognitive dysfunction in opioid-HIV comorbidity: Longitudinal and functional studies$697,583
R01 · FY2025 · DA
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity$678,736
R01 · FY2025 · DA · contact PI
Opioid and non-opioid receptor mechanisms in neurons and glia underlying fentanyl and HIV comorbidity in the striatum$661,789
R01 · FY2025 · DA · contact PI
pTau-related neuron and cognitive dysfunction in opioid-HIV comorbidity: Longitudinal and functional studies$697,583
R01 · FY2024 · DA
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity$678,736
R01 · FY2024 · DA · contact PI
Opioid and non-opioid receptor mechanisms in neurons and glia underlying fentanyl and HIV comorbidity in the striatum$661,789
R01 · FY2024 · DA · contact PI
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity$678,736
R01 · FY2023 · DA · contact PI
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injury$615,666
R01 · FY2023 · DA
Chloride channel-dependent mechanisms of opiate and HIV-induced synaptodendritic injury$232,875
R21 · FY2023 · DA
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity$678,736
R01 · FY2022 · DA · contact PI
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injury$615,666
R01 · FY2022 · DA
Selective vulnerability of discrete neural circuits in the striatum to HIV-opiate comorbidity$416,009
R01 · FY2022 · DA · contact PI
Chloride channel-dependent mechanisms of opiate and HIV-induced synaptodendritic injury$194,063
R21 · FY2022 · DA
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injury$615,666
R01 · FY2021 · DA
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection$567,877
R01 · FY2021 · DA
HIV opiate interactions in white matter pathology$514,511
R01 · FY2021 · DA · contact PI
Selective vulnerability of discrete neural circuits in the striatum to HIV-opiate comorbidity$416,009
R01 · FY2021 · DA · contact PI
Mechanisms of opiate drug-HIV-induced neurodegeneration$355,296
R01 · FY2021 · DA · contact PI
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injury$615,666
R01 · FY2020 · DA
HIV opiate interactions in white matter pathology$580,492
R01 · FY2020 · DA · contact PI
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection$567,877
R01 · FY2020 · DA
Selective vulnerability of discrete neural circuits in the striatum to HIV-opiate comorbidity$416,009
R01 · FY2020 · DA · contact PI
Mechanisms of opiate drug-HIV-induced neurodegeneration$355,296
R01 · FY2020 · DA · contact PI
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injury$615,583
R01 · FY2019 · DA
HIV opiate interactions in white matter pathology$580,492
R01 · FY2019 · DA · contact PI
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection$567,877
R01 · FY2019 · DA
S1P Receptor Mechanisms in Neuropathic Pain$541,645
R01 · FY2019 · NS
Selective vulnerability of discrete neural circuits in the striatum to HIV-opiate comorbidity$415,680
R01 · FY2019 · DA · contact PI
Mechanisms of opiate drug-HIV-induced neurodegeneration$355,296
R01 · FY2019 · DA · contact PI
HIV opiate interactions in white matter pathology$529,386
R01 · FY2018 · DA · contact PI
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection$507,931
R01 · FY2018 · DA
S1P Receptor Mechanisms in Neuropathic Pain$500,578
R01 · FY2018 · NS
S1P Receptor Mechanisms in Neuropathic Pain$411,286
R01 · FY2018 · NS
Selective vulnerability of discrete neural circuits in the striatum to HIV-opiate comorbidity$378,058
R01 · FY2018 · DA · contact PI
Mechanisms of opiate drug-HIV-induced neurodegeneration$326,556
R01 · FY2018 · DA · contact PI
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 Comorbidity$130,345
K02 · FY2018 · DA · contact PI
HIV opiate interactions in white matter pathology$529,386
R01 · FY2017 · DA · contact PI
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection$507,931
R01 · FY2017 · DA
S1P Receptor Mechanisms in Neuropathic Pain$484,727
R01 · FY2017 · NS
Regulation of HIV and opiate-directed synaptodendritic injury/death in striatum$438,027
R01 · FY2017 · DA · contact PI
Glial origins of HIV and opiate-driven synaptodendritic injury$430,485
R01 · FY2017 · DA
Mechanisms of opiate drug-HIV-induced neurodegeneration$326,556
R01 · FY2017 · DA · contact PI
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 Comorbidity$130,345
K02 · FY2017 · DA · contact PI
S1P Receptor Mechanisms in Neuropathic Pain$475,313
R01 · FY2016 · NS
Glial origins of HIV and opiate-driven synaptodendritic injury$462,701
R01 · FY2016 · DA
Regulation of HIV and opiate-directed synaptodendritic injury/death in striatum$428,881
R01 · FY2016 · DA · contact PI
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 Comorbidity$130,345
K02 · FY2016 · DA · contact PI
Glial origins of HIV and opiate-driven synaptodendritic injury$465,718
R01 · FY2015 · DA
Regulation of HIV and opiate-directed synaptodendritic injury/death in striatum$421,974
R01 · FY2015 · DA · contact PI
S1P Receptor Mechanisms in Neuropathic Pain$396,661
R01 · FY2015 · NS
Chemical Probes on NeuroAIDS$225,318
R21 · FY2015 · DA
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 Comorbidity$130,345
K02 · FY2015 · DA · contact PI
Glial origins of HIV and opiate-driven synaptodendritic injury$472,811
R01 · FY2014 · DA
Regulation of HIV and opiate-directed synaptodendritic injury/death in striatum$430,333
R01 · FY2014 · DA · contact PI
Mechanisms of Opiate Drug-HIV-Induced Neurodegeneration$358,752
R01 · FY2014 · DA · contact PI
Chemical Probes on NeuroAIDS$190,625
R21 · FY2014 · DA
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 Comorbidity$130,345
K02 · FY2014 · DA · contact PI
Glial origins of HIV and opiate-driven synaptodendritic injury$443,305
R01 · FY2013 · DA
Regulation of HIV and opiate-directed synaptodendritic injury/death in striatum$395,701
R01 · FY2013 · DA · contact PI
Mechanisms of Opiate Drug-HIV-Induced Neurodegeneration$344,542
R01 · FY2013 · DA · contact PI
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 Comorbidity$129,082
K02 · FY2013 · DA · contact PI
Mechanisms of Opiate Drug-HIV-Induced Neurodegeneration$359,038
R01 · FY2012 · DA · contact PI
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 Comorbidity$129,082
K02 · FY2012 · DA · contact PI
Mechanisms of Opiate Drug-HIV-Induced Neurodegeneration$359,172
R01 · FY2011 · DA · contact PI
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 Comorbidity$129,082
K02 · FY2011 · DA · contact PI
Mechanisms of Opiate Drug-HIV-Induced Neurodegeneration$347,011
R01 · FY2010 · DA · contact PI
Fractalkine as a therapeutic for opioid accelerated neurotoxicity in HIV$216,078
R21 · FY2010 · DA · contact PI
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 Comorbidity$129,082
K02 · FY2010 · DA · contact PI
Opiate drug abuse and CNS vulnerability to HIV$1,017,092
P01 · FY2009 · DA · contact PI
Fractalkine as a therapeutic for opioid accelerated neurotoxicity in HIV$181,003
R21 · FY2009 · DA · contact PI
Mechanisms of Opiate Drug-HIV-Induced Neurodegeneration$173,068
R01 · FY2009 · DA · contact PI
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 Comorbidity$129,082
K02 · FY2009 · DA · contact PI
Opiate drug abuse and CNS vulnerability to HIV$995,804
P01 · FY2008 · DA · contact PI
Mechanisms of Opiate Drug-HIV-Induced Neurodegeneration$173,068
R01 · FY2008 · DA · contact PI
Opiate drug abuse and CNS vulnerability to HIV$994,858
P01 · FY2007 · DA · contact PI
Mechanisms of Opiate Drug-HIV-Induced Neurodegeneration$173,636
R01 · FY2007 · DA · contact PI
Opiate drug abuse and CNS vulnerability to HIV$988,298
P01 · FY2006 · DA · contact PI
Mechanisms of Opiate Drug-HIV-Induced Neurodegeneration$178,822
R01 · FY2006 · DA · contact PI
Opiate drug abuse and CNS vulnerability to HIV$1,029,917
P01 · FY2005 · DA
Mechanisms of Opiate Drug-HIV-Induced Neurodegeneration$182,916
R01 · FY2005 · DA
OPIOIDS AND CENTRAL NERVOUS SYSTEM VULNERABILITY TO HIV$289,600
R01 · FY2004 · DA
OPIATES--NEURONAL AND GLIAL VULNERABILITY TO HIV$253,400
R01 · FY2004 · DA
OPIOIDS AND CENTRAL NERVOUS SYSTEM VULNERABILITY TO HIV$289,600
R01 · FY2003 · DA
OPIATES--NEURONAL AND GLIAL VULNERABILITY TO HIV$253,400
R01 · FY2003 · DA
OPIOIDS AND CENTRAL NERVOUS SYSTEM VULNERABILITY TO HIV$289,600
R01 · FY2002 · DA
OPIATES--NEURONAL AND GLIAL VULNERABILITY TO HIV$253,400
R01 · FY2002 · DA
OPIOIDS AND CENTRAL NERVOUS SYSTEM VULNERABILITY TO HIV$289,633
R01 · FY2001 · DA
OPIATES--NEURONAL AND GLIAL VULNERABILITY TO HIV$253,400
R01 · FY2001 · DA
OPIOIDS AND CENTRAL NERVOUS SYSTEM VULNERABILITY TO HIV$290,000
R01 · FY2000 · DA
OPIATES--NEURONAL AND GLIAL VULNERABILITY TO HIV$253,720
R01 · FY2000 · DA
ABUSED OPIATE DRUGS AND NEURAL DEVELOPMENT$162,960
R01 · FY2000 · DA